Anticoagulant fusion protein anchored to cell membrane
CA 2285702 C · Owner: Imperial College Innovations Limited · Inventors: Riesbeck, Kristian; Dorling, Anthony; George, Andrew John Timothy
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to the inhibition of blood coagulation especially , during organ rejection, and in particular the inhibition of delayed vascular rejection. The invention provides anticoagulant proteins which are anchored to cell membranes. The anticoagulant function is preferably provided by heparin antithrombin, hirudin, TFPI, tick anticoagulant peptide or a snake venom , factor. These anticoagulant proteins are preferably prevented from being constitutively expressed at the cell surface. In particular expression at the , cell surface is regulated according to cell activation for instance by , targeting the protein to a suitable secretory granule. Expression of these proteins …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 26, 1998 and granted June 28, 2016. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 26, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 26, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.